Clinical trial
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With…
NCT02399085 · MorphoSys AG, Industry · Completed
Key facts
| NCT number | NCT02399085 |
|---|---|
| Title | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL |
| Official title | A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) |
| Acronym | L-MIND |
| Lead sponsor | MorphoSys AG, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Tafasitamab, Lenalidomide |
| Enrollment | 81 |
| Start date | Mar 29, 2016 |
| Primary completion | Nov 14, 2022 |
| Completion | Apr 19, 2023 |
| First posted | Mar 26, 2015 |
| Last update posted | Oct 23, 2023 |
| Countries | Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: